Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Some common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer. Prostate cancer (PCa) is the fourth most common cancer across the US in terms of occurrence. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. Prostate cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.
Novartis and Jubilant Pharma – Notable Market Players in Prostate Cancer Nuclear Medicine Diagnostics Market
The Prostate Cancer Nuclear Medicine Diagnostics market majorly consists of the players such as Blue Earth Diagnostics Limited, ImaginAB, Curium, Juniliant Radiopharma, NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH, Telix Pharmaceuticals Ltd., Novartis AG, Theragonostics, and Lantheus Medical Imaging Inc. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized strategies such as product launches, expansions, and product upgradations for the growth of their organizations. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.
Below is the list of the growth strategies done by the players operating in the Prostate Cancer Nuclear Medicine Diagnostics market:
| Year | News |
| Apr-22 | Telix announced partnership with Avanço and THP for the distribution of Telix’s prostate cancer investigational imaging product for the Portuguese and Austrian, Czech Republic and Slovak Republic markets. |
| Feb-22 | Telix announced that it has entered into a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Telix’s prostate cancer imaging product Illuccix (Kit for the preparation of 68Ga-PSMA-11) for the Australian market. |
| Sept-21 | Theragnostics announced that it has signed a global licensing agreement with Advanced Accelerator Applications S.A. (“AAA”), a Novartis company, to develop and commercialise Gallium-68 (Ga-68) one-step PET radiopharmaceuticals. This agreement enabled the company to accelerate the development of their own novel radionuclide therapy and diagnostic portfolio. |
| Jun-21 | Curium completed the acquisition of the Austrian radiopharmaceuticals Company IASON, further expanding its footprint in Europe for its broad portfolio of life saving diagnostic solutions. |
| Jan-21 | ImaginAb Announces CD8 ImmunoPET Technology License and Supply Agreement with Pfizer. ImaginAb Inc., a leading global producer of immuno-oncology imaging agents, announced a new multi-year, non-exclusive licence agreement with Pfizer Inc. to deliver the 89Zr CD8 Immuno-PET agent, which could be used to image CD8 T cells in cancer patients. |
| Nov-20 | Jubilant Radiopharma and SOFIE Biosciences Ink Strategic Partnership Deal to Further Advance the Field of Molecular Imaging & Therapeutics. According to the terms of the partnership, Jubilant Pharma, through one of its wholly owned subsidiaries, was a strategic partner to SOFIE, allowing SOFIE to continue to expand production capacity, advance its theranostic pipeline, and support novel PET diagnostic manufacturing and distribution in the United States. |
| Apr-22 | Telix announced that its prostate cancer imaging agent, Illuccix (kit for preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection, will be commercially available in the United States. |
